https://dsrv-platform.vercel.app Warning-letter analysis, 483 trend reports, and regulatory intelligence for pharma quality teams. en-us Mon, 01 Jun 2026 00:00:00 GMT https://dsrv-platform.vercel.app/articles/sato-aseptic-fda-warning-letter-dsrv-inspection-risk FDA’s May 18, 2026 warning letter to Sato Pharmaceutical describes six consecutive media-fill failures as a quality-system credibility collapse. The inspection-readiness lessons span ISO 5/RABS design, smoke studies, contamination prevention, and systemic CAPA, and they generalize far beyond Sato. Mon, 01 Jun 2026 00:00:00 GMT https://dsrv-platform.vercel.app/articles/sato-aseptic-fda-warning-letter-dsrv-inspection-risk https://dsrv-platform.vercel.app/articles/fda-483-response-15-business-days-investigation-quality FDA's March 2026 draft guidance converts the 483 response from a closeout ritual into a formal test of your investigation quality under 21 CFR 211.192. Sun, 24 May 2026 00:00:00 GMT https://dsrv-platform.vercel.app/articles/fda-483-response-15-business-days-investigation-quality https://dsrv-platform.vercel.app/articles/cohance-lifesciences-complaint-cleaning-warning-letter FDA's January 2026 warning letter to Cohance Lifesciences rejected a re-opened complaint investigation for the same gap it had the first time. The enforcement record documents what happens when a quality unit treats complaint handling and cleaning validation as separate systems. Tue, 19 May 2026 00:00:00 GMT https://dsrv-platform.vercel.app/articles/cohance-lifesciences-complaint-cleaning-warning-letter https://dsrv-platform.vercel.app/articles/eu-ai-act-omnibus-deadline-december-2027 EU lawmakers reached a provisional deal on May 7 to push the high-risk AI compliance deadline from August 2, 2026 to December 2, 2027. For pharma quality AI programs, the window is larger. The destination has not moved. Sat, 16 May 2026 00:00:00 GMT https://dsrv-platform.vercel.app/articles/eu-ai-act-omnibus-deadline-december-2027 https://dsrv-platform.vercel.app/articles/fda-ai-oneday-inspection-pilot-changes-inspection-readiness FDA's 1-day inspection pilot and AI-assisted risk ranking change what inspection readiness means for quality teams: less time to recover, more pressure on records that can stand on their own. Tue, 12 May 2026 00:00:00 GMT https://dsrv-platform.vercel.app/articles/fda-ai-oneday-inspection-pilot-changes-inspection-readiness https://dsrv-platform.vercel.app/articles/chemco-warning-letter-cleaning-component-controls FDA's April 2026 Chemco warning letter links visible residue, missing cleaning validation for shared equipment, and inadequate incoming component identity testing into one quality-system control failure. Mon, 20 Apr 2026 00:00:00 GMT https://dsrv-platform.vercel.app/articles/chemco-warning-letter-cleaning-component-controls https://dsrv-platform.vercel.app/articles/contract-testing-labs-cgmp-failures Two March 2026 FDA-linked signals point to the same problem: contract testing oversight is still being treated as a paperwork exercise instead of a release-critical control. Small quality teams should read these cases as a warning about supplier qualification, data trust, and batch disposition risk. Tue, 07 Apr 2026 00:00:00 GMT https://dsrv-platform.vercel.app/articles/contract-testing-labs-cgmp-failures https://dsrv-platform.vercel.app/articles/fda-data-integrity-remediation-demands When FDA's warning letters require independent assessments, patient-risk analyses, and global CAPA strategies, the agency is not just describing consequences. It is disclosing the standards it expected to find before the inspection started. Tue, 07 Apr 2026 00:00:00 GMT https://dsrv-platform.vercel.app/articles/fda-data-integrity-remediation-demands https://dsrv-platform.vercel.app/articles/usable-procedures-vs-defensible-quality-decisions Modern AI tools can make SOPs clearer and easier to follow. But inspectors do not cite companies for unclear formatting. They cite them for weak investigations, missing escalation logic, and decisions that cannot be traced to evidence. Usability and defensibility are different problems. Wed, 01 Apr 2026 00:00:00 GMT https://dsrv-platform.vercel.app/articles/usable-procedures-vs-defensible-quality-decisions https://dsrv-platform.vercel.app/articles/fda-483-response-draft-guidance-2026 FDA's March 2026 draft guidance formalizes for the first time what the agency expects in a 483 response — executive sign-off, risk assessment for distributed product, structured CAPA tables, and a 15-business-day window that is now explicitly tied to enforcement timelines. Tue, 24 Mar 2026 00:00:00 GMT https://dsrv-platform.vercel.app/articles/fda-483-response-draft-guidance-2026 https://dsrv-platform.vercel.app/articles/ich-q1-stability-guideline-2026 FDA's June 2025 draft ICH Q1 guidance consolidates the Q1A-F and Q5C stability guideline stack. It is still draft and not for implementation, but it signals where global stability expectations are moving. Fri, 20 Mar 2026 00:00:00 GMT https://dsrv-platform.vercel.app/articles/ich-q1-stability-guideline-2026 https://dsrv-platform.vercel.app/articles/fda-data-integrity-warning-letters-2026 Data integrity citations appeared in over 60% of pharmaceutical manufacturing warning letters in 2025. FDA is citing the systems that allowed falsification to happen unchallenged — not just the falsification itself. Here is what the enforcement record shows and what separates sites that pass from those that don't. Sat, 14 Mar 2026 00:00:00 GMT https://dsrv-platform.vercel.app/articles/fda-data-integrity-warning-letters-2026 https://dsrv-platform.vercel.app/articles/ich-q14-analytical-procedure-development ICH Q14 introduces a structured, science-based approach to analytical procedure development. We break down the key concepts, lifecycle management requirements, and how they align with existing Q2 and Q12 guidelines. Sun, 01 Mar 2026 00:00:00 GMT https://dsrv-platform.vercel.app/articles/ich-q14-analytical-procedure-development https://dsrv-platform.vercel.app/articles/risk-based-cleaning-validation-ich-q9 Cleaning validation remains one of the most inspection-cited areas in pharmaceutical manufacturing. This article explores how a risk-based framework under ICH Q9 Rev.1 can rationalise your validation strategy. Sun, 01 Feb 2026 00:00:00 GMT https://dsrv-platform.vercel.app/articles/risk-based-cleaning-validation-ich-q9 https://dsrv-platform.vercel.app/articles/fda-real-time-release-testing-rtrt The FDA has issued new draft guidance on RTRT as part of its modernisation initiative. We examine the regulatory pathway, technical requirements, and what this means for PAT-enabled manufacturing lines. Thu, 01 Jan 2026 00:00:00 GMT https://dsrv-platform.vercel.app/articles/fda-real-time-release-testing-rtrt